Indivior PLC (NASDAQ:INDV – Get Free Report) CAO Woodrow Anderson acquired 1,500 shares of the stock in a transaction on Wednesday, August 5th. The shares were purchased at an average price of $36.28 per share, for a total transaction of $54,420.00. Following the transaction, the chief accounting officer directly owned 26,138 shares in the company, valued at approximately $948,286.64. This trade represents a 6.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Indivior Stock Performance
INDV stock opened at $38.73 on Thursday. Indivior PLC has a 52 week low of $21.48 and a 52 week high of $42.81. The company has a market capitalization of $4.57 billion, a PE ratio of 13.88 and a beta of 0.86. The company’s 50-day simple moving average is $39.18 and its 200 day simple moving average is $35.57.
Indivior (NASDAQ:INDV – Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. The firm had revenue of $343.00 million for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
Several analysts have recently issued reports on the company. Barclays reduced their target price on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 24th. Finally, Craig Hallum reissued a “buy” rating and issued a $53.00 target price on shares of Indivior in a report on Tuesday. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.17.
Get Our Latest Analysis on INDV
Indivior Company Profile
Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.
Read More
- Five stocks we like better than Indivior
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
